Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
NEW YORK, May 10, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of TherapeuticsMD, Inc. (“TherapeuticsMD”) (NYSEMKT:TXMD) between July 7, 2016 and April 9, 2017. You are hereby notified that Levi & Korsinsky has commenced the action Paoli v. TherapeuticsMD, Inc., et al. (Case No. 9:17-cv-80473-RLR) in the USDC for the Southern District of Florida. To get more information go to:
http://www.zlk.com/pslra-sa/therapeuticsmd-inc?wire=1
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that, throughout the class period, TherapeuticsMD engaged in a scheme to deceive the market and cause the Company’s stock to trade at artificially inflated prices. In particular, the complaint alleges that TherapeuticsMD made false and/or misleading statements and/or failed to disclose that: (i) the Company’s New Drug Application (NDA) submission for TX-004HR was deficient; (ii) the NDA submission for TX-004HR was not supported by the complete TX-004HR clinical program and/or the clinical program was deficient; (iii) the deficient NDA would likely cause a delay of the FDA’s potential approval of the TX-004HR NDA.
On April 10, 2017, TherapeuticsMD issued a press release announcing that the U.S. Food and Drug Administration had identified deficiencies in its NDA for TX-004HR. Following this news, shares of TherapeuticsMD fell more than 19% to close at $6.20 per share on April 10, 2017.
Take Action: if you suffered a loss in TherapeuticsMD you have until June 19, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
